ES2169420T3 - Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para tratar enfermedades proliferativas. - Google Patents

Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para tratar enfermedades proliferativas.

Info

Publication number
ES2169420T3
ES2169420T3 ES97941474T ES97941474T ES2169420T3 ES 2169420 T3 ES2169420 T3 ES 2169420T3 ES 97941474 T ES97941474 T ES 97941474T ES 97941474 T ES97941474 T ES 97941474T ES 2169420 T3 ES2169420 T3 ES 2169420T3
Authority
ES
Spain
Prior art keywords
protein
inhibit
useful
function
proliferative diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97941474T
Other languages
English (en)
Inventor
Dinanath F Rane
Alan K Mallams
Arthur G Taveras
F George Njoroge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2169420T3 publication Critical patent/ES2169420T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA (1.0), A SU UTILIZACION COMO INHIBIDOR DE LA FARNESIL PROTEIN TRANSFERASA Y A PREPARACIONES FARMACEUTICAS QUE LOS CONTIENEN, Y EN PARTICULAR A COMPUESTOS DE FORMULA (1.5A) EN LA QUE R 1 , R S UP,2 Y R 3 SON HALOGENOS, A Y B SON CADA UNO H 2 , Y R ES TAL COMO SE DEFINE EN LA DESCRIPCION.
ES97941474T 1996-09-13 1997-09-11 Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para tratar enfermedades proliferativas. Expired - Lifetime ES2169420T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71332696A 1996-09-13 1996-09-13

Publications (1)

Publication Number Publication Date
ES2169420T3 true ES2169420T3 (es) 2002-07-01

Family

ID=24865700

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97941474T Expired - Lifetime ES2169420T3 (es) 1996-09-13 1997-09-11 Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para tratar enfermedades proliferativas.

Country Status (20)

Country Link
EP (1) EP0927178B1 (es)
JP (1) JP3152438B2 (es)
KR (1) KR20000036059A (es)
CN (1) CN1237169A (es)
AT (1) ATE213736T1 (es)
AU (1) AU729810B2 (es)
BR (1) BR9712819A (es)
CA (1) CA2264569C (es)
CZ (1) CZ83499A3 (es)
DE (1) DE69710741T2 (es)
ES (1) ES2169420T3 (es)
HU (1) HUP9904067A2 (es)
ID (1) ID22045A (es)
IL (1) IL128949A0 (es)
NO (1) NO991230L (es)
NZ (1) NZ334340A (es)
PL (1) PL332240A1 (es)
SK (1) SK33199A3 (es)
TR (1) TR199900561T2 (es)
WO (1) WO1998011096A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037619A1 (en) 1998-01-21 1999-07-29 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6613905B1 (en) 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
ATE309249T1 (de) 1998-01-21 2005-11-15 Millennium Pharm Inc Chemokin rezeptor antagonisten und verwndung
US6509346B2 (en) 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6503926B2 (en) 1998-09-04 2003-01-07 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7271176B2 (en) 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US6288083B1 (en) 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
US7417026B2 (en) 2003-08-13 2008-08-26 Children's Hospital Medical Center Mobilization of hematopoietic cells
US7550478B2 (en) 2005-06-23 2009-06-23 Merck & Co. Inc. Tyrosine kinase inhibitors
TW200813021A (en) 2006-07-10 2008-03-16 Merck & Co Inc Tyrosine kinase inhibitors
TW201024283A (en) * 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
JP6959332B2 (ja) 2016-09-27 2021-11-02 ミッション セラピューティクス リミティド Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48750A1 (en) * 1993-10-15 1998-05-18 Schering Corp Tricyclic carbonate compounds useful for inhabition of g-protein function for treatment of proliferative diseases
EP0723539B1 (en) * 1993-10-15 2001-12-12 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them

Also Published As

Publication number Publication date
KR20000036059A (ko) 2000-06-26
SK33199A3 (en) 1999-12-10
JP3152438B2 (ja) 2001-04-03
IL128949A0 (en) 2000-02-17
CA2264569C (en) 2003-11-11
JP2000502727A (ja) 2000-03-07
ATE213736T1 (de) 2002-03-15
EP0927178B1 (en) 2002-02-27
AU4337397A (en) 1998-04-02
ID22045A (id) 1999-08-26
DE69710741T2 (de) 2002-10-24
NZ334340A (en) 2000-09-29
DE69710741D1 (de) 2002-04-04
HUP9904067A2 (hu) 2000-05-28
PL332240A1 (en) 1999-08-30
BR9712819A (pt) 1999-11-23
AU729810B2 (en) 2001-02-08
EP0927178A1 (en) 1999-07-07
CA2264569A1 (en) 1998-03-19
CZ83499A3 (cs) 1999-07-14
WO1998011096A1 (en) 1998-03-19
NO991230L (no) 1999-05-14
NO991230D0 (no) 1999-03-12
CN1237169A (zh) 1999-12-01
HK1018267A1 (en) 1999-12-17
TR199900561T2 (xx) 1999-06-21

Similar Documents

Publication Publication Date Title
UY24805A1 (es) Peptidos y compuestos que se enlazan al receptor de la trombopoyetina
ES2098140T3 (es) Liosferas que contienen gonadotropina.
PT1254899E (pt) Derivados de piperazina e sua utilizacao como agentes anti-inflamatorios
BG104247A (bg) Производни на резорцинола
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
MX174420B (es) Uso de derivados de quinolina para la proteccion de plantas cultivadas
SV1996000114A (es) Nuevos plaguicidas
ES2183331T3 (es) Inhibidores de sulfamida-metaloproteasa.
BR9910908A (pt) Indenopirrolocarbazóis ligados em ponte
ES2110414T3 (es) Derivados de sacarina utiles como inhibidores de enzimas proteoliticas y su preparacion.
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
CY1106444T1 (el) 17b-νιτρο-11β-αρυλοστepοειδη και παραγωγα αυτων ως ορμονικοι αγωνιστες ή ανταγωνιστες
EE04055B1 (et) Ühendid ja kompositsioonid seriinproteaasse, eriti trüptaasse aktiivsusega seotud haiguste raviks, ja nende kasutamine
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
AR010565A1 (es) Moleculas de acido nucleico aislados, proteina aislada, formulaciones que las contienen, composicion terapeutica, uso de un compuesto protector y uninhibidor para preparar una composicion terapeutica, metodo para producir una proteina de carboxilesterosa, metodo para identificar compuestos, equipo d
DK0417003T3 (da) Anvendelse af antiprogestomimetiske forbindelser til fremme af ovulation
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
ES2150461T3 (es) Derivados de amidinofenilalanina, proceso para su preparacion, su empleo y agentes que los contienen como anticoagulantes.
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
PT928197E (pt) Utilizacao de proteinas como agentes contra doencas de natureza autoimunitaria
SE9604582D0 (sv) Novel compounds
BR9806193A (pt) Composição bi-aromáticos ligados por um radical heteroetinileno e composições farmacêuticas e cosméticas que os contêm
ES2067816T3 (es) Derivados de dialcoxibencilidenalcanfor.
MX9700854A (es) Derivados de azabicicloheptano n-substituidos utiles como neurolepticos.
BE866830A (fr) Proteine de soja modifiee

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 927178

Country of ref document: ES